MBRX - Moleculin Biotech, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.2700
+0.0100 (+0.79%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.2600
Open1.2600
Bid1.26 x 4000
Ask1.27 x 1800
Day's Range1.2600 - 1.3100
52 Week Range1.0300 - 3.3400
Volume190,237
Avg. Volume328,018
Market Cap34.454M
Beta (3Y Monthly)1.19
PE Ratio (TTM)N/A
EPS (TTM)-0.50
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.50
Trade prices are not sourced from all markets
  • ACCESSWIRE4 days ago

    Today's Research Reports on Trending Tickers: NeuroMetrix and Moleculin

    NEW YORK, NY / ACCESSWIRE / December 12, 2018 / NeuroMetrix and Moleculin were both up almost 19% in Tuesday’s trading session. Traders were gearing up for Moleculin’s conference call today discussing a recent discovery of a use of one of its molecules for cancer treatment while NeuroMetrix announced an update on its strategic collaboration with GSK Consumer Healthcare. NeuroMetrix, Inc. shares were up nearly 19% on almost 1.7 million shares traded on Tuesday.

  • GlobeNewswire5 days ago

    REMINDER: Moleculin Announces Conference Call to Discuss Recent Breakthrough Discovery and FDA Filing on Wednesday, December 12, 2018

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced a reminder it will host a conference call to discuss the recent discovery of a use of one of its molecules for cancer treatment and provide a business update. Participants can dial (800) 860-2442 or (412) 858-4600 to access the conference call, or can listen via a live Internet web cast, which is available in the Investor Relations section of the Company's website at www.moleculin.com. A webcast replay will be available in the Investors section of the Company’s website at www.moleculin.com for 90 days.

  • GlobeNewswire9 days ago

    Moleculin Announces Conference Call to Discuss FDA Filing and New Immune Checkpoint Data on Wednesday, December 12, 2018

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it will host a conference call to discuss the recent discovery of a use of one its molecule for cancer treatment and provide a business update. Participants can dial (800) 860-2442 or (412) 858-4600 to access the conference call, or can listen via a live Internet web cast, which is available in the Investor Relations section of the Company's website at www.moleculin.com. A webcast replay will be available in the Investors section of the Company’s website at www.moleculin.com for 90 days.

  • GlobeNewswire10 days ago

    Moleculin Announces FDA Filing for Orphan Drug Designation for Glioblastoma Drug

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has filed a request with the U.S. Food and Drug Administration (“FDA”) for Orphan Drug Status for its drug candidate WP1066.

  • GlobeNewswire12 days ago

    Moleculin Announces Breakthrough Discovery for its WP1066

    Walter Klemp, Moleculin’s Chairman and CEO added, “This potential was initially reported in a 2017 Japanese study (Journal of clinical and experimental hematopathology, Vol. 57 No.1, 21-25, 2017), but we have now been able to confirm this activity with our own sponsored research at MD Anderson.  Also, very recent independent research (Front Pharmacol.

  • GlobeNewswire18 days ago

    Moleculin Announces New Data Further Supporting Its Lead Drug for Treating Pancreatic Cancer

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that data from an independent test in animal models confirmed, as previously believed, that its immuno-stimulating STAT3 inhibitor achieves disproportionately high accumulation in the pancreas. Walter Klemp, Moleculin’s Chairman and CEO added, “Published research shows that the growth and survival of pancreatic cancer requires activated STAT3 (p-STAT3) and our own research suggests that WP1732 may be one of the most effective inhibitors of p-STAT3 that has demonstrated activity in in vivo models.  Confirming the disproportionately high accumumulation of WP1732 in the pancreas puts us one step closer to introducing an entirely new approach to treating pancreatic cancer.  This is very encouraging and confirms the direction that Moleculin has taken with WP1732.

  • GlobeNewswire27 days ago

    Consolidated Research: 2018 Summary Expectations for Moleculin Biotech, Novan, PAVmed, Maui Land & Pineapple, Hallmark Financial Services, and McEwen Mining — Fundamental Analysis, Key Performance Indications

    NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswirelast month

    Moleculin Requests FDA Meeting Regarding IND for New Cancer Drug

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has filed a request with the US Food and Drug Administration (FDA) for a Pre-Investigational New Drug (IND) Meeting to seek FDA’s guidance and concurrence that the WP1732 development plan will meet requirements for an Initial IND filing and initiation of a proposed Phase 1 clinical trial.

  • GlobeNewswirelast month

    Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2018

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center, today announced its financial results for the third quarter ended September 30, 2018. Additionally, the Company announced potential upcoming milestones and recent corporate developments. Walter Klemp, Chairman and CEO of Moleculin, said, “We maintain a sharp focus on the continuing development of our broad-based oncology portfolio and in effectively advancing those solutions through the FDA regulatory process.

  • GlobeNewswirelast month

    Moleculin Announces New Independent Study Expands Potential Use of Its Pancreatic Drug Candidate WP1122

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that a new mechanism of action may have been uncovered expanding the potential use of its inhibitor of glycolysis, WP1122.

  • GlobeNewswirelast month

    Moleculin Announces Significant Milestone Achieved in Glioblastoma Trial

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced positive progress in the Phase 1 clinical trial of its immuno-stimulating STAT3 inhibitor, WP1066, with initial results showing bioavailability of the drug in patients. Walter Klemp, Moleculin’s Chairman and CEO added, “We believe WP1066 is a first-in-class compound capable of stimulating a natural immune response in animal models while directly attacking tumors by modulating transcriptional activity and repressing what we call ‘oncogenic transcription factors.’  Chief among these is STAT3, considered a master regulator of tumor progression.  While activity in animal models has been very promising, one of the goals of this trial was to determine the potential for bioavailability in humans.  The initial positive indications of this clinical trial increase our confidence that WP1066 has the potential to become an important drug in the treatment of certain cancers.

  • GlobeNewswire2 months ago

    Moleculin Announces Positive Data on WP1066 in Pre-Clinical Trials

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that investigators at Emory University will present animal model data supporting the potential of WP1066 to treat pediatric brain tumors at the upcoming Society for Neuro-Oncology Annual Scientific Meeting.

  • GlobeNewswire2 months ago

    Moleculin Announces New Data Discovery Confirming Significant Increase in Potential to Starve Cancerous Tumors

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that new data relating to its molecule WP1122 will be presented at the upcoming Society for Neuro-Oncology Annual Scientific Meeting. Walter Klemp, Moleculin’s Chairman and CEO added, “Metabolic inhibition of tumors is conceptually a very important approach, and we believe we have a clear translational focus.

  • Benzinga6 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Winnebago Industries, Inc. (NYSE: WGO ) stock was ...